AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. Both also recently saw their shares fall significantly in ...

AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. TipRanks is the most comprehensive ...

ALIA-1758 is under clinical development by Aliada Therapeutics and currently in Phase I for Alzheimer's Disease.

today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics. Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate ...

AbbVie announced the completion of its acquisition of Aliada Therapeutics. 1 As a result, Aliada’s lead investigational asset, ALIA-1758, is an Alzheimer’s treatment that’s in Phase 1 trials and will ...

Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.